These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25432275)

  • 1. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
    Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.
    Patel N; Nasiri M; Koroglu A; Bliss S; Davis M; McNutt LA; Miller C
    Infect Dis Ther; 2015 Jan; 4(1):67-78. PubMed ID: 25708155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients.
    Ahmed A; Schriever C; Britt N; Yager J; Amin R; McGuey L; Patel N
    Ann Hepatol; 2019; 18(4):601-606. PubMed ID: 31078440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
    Shiffman ML; James AM; Long AG; Alexander PC
    Am J Gastroenterol; 2015 Aug; 110(8):1179-85. PubMed ID: 26215530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
    Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
    HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.
    Jakeman B; Nasiri M; Ruth L; Morse C; Mahatme S; Patel N
    Ann Pharmacother; 2017 May; 51(5):365-372. PubMed ID: 28367698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting.
    Campos-Varela I; Peters MG; Terrault NA
    Clin Infect Dis; 2015 Jan; 60(1):108-16. PubMed ID: 25228702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rapid evolution of treatment strategies for hepatitis C.
    Muir AJ
    Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
    Flanagan S; Crawford-Jones A; Orkin C
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The high price of the new hepatitis C virus drugs.
    Steinbrook R; Redberg RF
    JAMA Intern Med; 2014 Jul; 174(7):1172. PubMed ID: 24798183
    [No Abstract]   [Full Text] [Related]  

  • 16. New drugs: simeprevir, sofosbuvir, and dolutegravir sodium.
    Hussar DA; Jin ZJ
    J Am Pharm Assoc (2003); 2014; 54(2):202-7. PubMed ID: 24632934
    [No Abstract]   [Full Text] [Related]  

  • 17. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
    Campos-Varela I; Straley S; Agudelo EZ; Carlson L; Terrault NA
    Liver Transpl; 2015 Feb; 21(2):272-4. PubMed ID: 25332190
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
    Sockalingam S; Sheehan K; Feld JJ; Shah H
    Am J Psychiatry; 2015 Jun; 172(6):512-6. PubMed ID: 26029803
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.
    Poizot-Martin I; Naqvi A; Obry-Roguet V; Valantin MA; Cuzin L; Billaud E; Cheret A; Rey D; Jacomet C; Duvivier C; Pugliese P; Pradat P; Cotte L;
    PLoS One; 2015; 10(10):e0141164. PubMed ID: 26488159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new era in therapy of chronic hepatitis C].
    Füessl HS
    MMW Fortschr Med; 2015 Feb; 157(2):38. PubMed ID: 25743515
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.